Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
ProteoMediX
ProteoMediX is a spinoff from ETH Zurich specializing in identifying new biomarkers for early cancer detection.
Sector
Subsector
Location
total rounds
total raised
Haystack Oncology
Haystack Oncology is a liquid biopsy diagnostic company that uses a proprietary assay to detect residual disease in cancer patients.
Sector
Subsector
Keywords
Location
total rounds
total raised
Viomics
Viomics is a molecular diagnostics company that develops and delivers groundbreaking cancer detection applications for early intervention.
Sector
Subsector
Keywords
HealthTell
HealthTell is a start-up that develops tools to monitor health status with a simple and inexpensive test from a single drop of blood.
Sector
Subsector
Location
total rounds
total raised
Financials
Funding Rounds4
Number of Funding Rounds
Money Raised
Their latest funding was raised on 25.07.2023. Their latest investor EDBI. Their latest round Series D
China Fellow Partners
China Fellow Partners is an investment firm that specializes in VC, PE, mergers and acquisitions, and asset management.
Sector
Subsector
Keywords
Location
count Of Investments
CDG Capital
CDG Capital is a boutique investment banking firm that offers financial advisory services to private, institutional, and corporate clients.
Sector
Subsector
Keywords
Location
count Of Investments
New Horizons Venture Capital
New Horizons Venture Capital invests in early-stage firms with unique models that generate sustainable earnings.
Sector
Subsector
Location
count Of Investments
count Of Exists
CR-CP Life Science Fund
CR-CP Life Science Fund is a joint venture that invests in life science companies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Investments1
Med247
Med247 is a healthcare startup that offers a platform for customers to book appointments and consult with professional doctors online.
Sector
Subsector
Location
total rounds
total raised
Co-Investors
Investors15
Number of lead investors
Number of investors
EDBI
EDBI is a Singapore-based global investor in high-growth technology sectors.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Chu Swee Yeok
Ms Chu joined EDB Investments Pte Ltd (EDBI) as its Chief Executive Officer in late 2008, bringing with her over 20 years of track record and extensive experience in equity investments of start-up to growth and late-stage ventures, strategic planning, business and technology development.. Prior to EDBI, Ms Chu was the CEO of Bio*One Capital Pte Ltd since 2004. Under her leadership, Bio*One became a globally recognised and reputable investment fund manager with a portfolio of over 50 therapeutics, medical technology and services companies worldwide and in Singapore. Previously Ms Chu held major stints at the Singapore Economic Development Board (SEDB) and the Agency for Science & Technology Research where she played a pioneering role in developing and implementing key industry and R&D strategies leading to the growth of the biomedical sector as a major pillar of Singapore's economy today. At SEDB she was instrumental in establishing several venture funds since 1990 and providing oversight to their management. Ms Chu was also responsible for many successful negotiations with global MNCs relating to their R&D, manufacturing and headquarters activities in Singapore. Besides the board of EDBI, Ms Chu also serves on the boards of Merlion Pharmaceuticals Pte Ltd, Singapore-Suzhou Township Development Pte Ltd, and Alexandra Health Endowment Fund.
current job
Mike Chen
Mike is a co-founder and Managing Partner of the micro venture capital firm New Highlands Ventures (NHV), and the President and board member of Seattle Venture Investment Alliance (SVIA). Mike has been an active investor and advisor to many start-ups for many years, he has more than 20 years of corporate business development, major contract negotiations, and strategic sourcing experience in high tech industry. Companies he held sr. positions with included CITIC Investments in China, and Intel and Microsoft in the United States. In late 90s Mike invested early on in Yahoo and Geo Cities with very successful returns. Besides investing, Mike also helps companies doing M&A activities in USA. Mike graduated from the Business School of Sun Yat-Sen University and earned an MBA degree from USA.
current job
count Of Investments
The Agency for Science, Technology and Research
A*STAR is Singapore's lead agency for fostering world-class scientific research and talent.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
People
Founders4
Zhou Lihan
Lihan is the Founder and co-CEO of ark. In 2014, Lihan co-founded and served as CEO of MiRXES, a biotech startup developing microRNA technologies and cancer detection tests. He oversaw MiRXES’ operations in Singapore and China, and managed collaborations with leading clinical consortia and pharmaceutical companies in developing microRNA based diagnostic assays. MIRXES was recognized as Singapore’s Most Promising Startup 2016 by the Emerging Enterprise Award. Prior to founding MiRXES, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel microRNA qPCR assay platform and an integrated workflow for biomarker discovery. Lihan has a PhD in Biochemistry from the National University of Singapore. He has authored and co-authored more than 20 peer-reviewed publications and 8 patent applications. Lihan was recently recognized by the MIT Technology Review as a member of the Innovators Under 35.
current job
Zhou Lihan
Employee Profiles4
Activity
Recent News2
The graph reveals the ratio (%) of positive news articles in a chosen time range